Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Characterization of a Human Bone Marrow-Derived CRISPR/Cas9 Cell Model for Chronic Myeloid Leukemia

Pia Christin Radszuweit, Barbara Mankel, Fulya Korkmaz, Hildegard Keppeler, Claudia Lengerke, Dominik Schneidawind, Corina Schneidawind

Blood (2024) 144 (Supplement 1): 1353.

https://doi.org/10.1182/blood-2024-209947

Published: 2024

Journal Articles

Tisagenlecleucel for the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Interim Report of the European Post-Authorisation Safety Study Conducted By EBMT

Blood (2024) 144 (Supplement 1): 607.

https://doi.org/10.1182/blood-2024-200367

Published: 2024

Journal Articles

Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification - an EBMT ALWP Study

Blood (2024) 144 (Supplement 1): 4945.

https://doi.org/10.1182/blood-2024-204824

Published: 2024

Journal Articles

High Body Mass Index Is Associated with Favorable Outcome in Younger Patients Receiving CD19 CAR T-Cell Therapy for B-Cell Lymphoma: A Retrospective Study from the EBMT Transplant Complications Working Party

Blood (2023) 142 (Supplement 1): 4867.

https://doi.org/10.1182/blood-2023-187393

Published: 2023

Journal Articles

Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Blood (2023) 142 (10): 865–877.

https://doi.org/10.1182/blood.2023020578

Published: 2023

Includes: Supplemental data

Journal Articles

Induction of t(9;22) (q34;q11) in Bone Marrow-Derived HSPCs Via CRISPR/Cas9 to Reveal the Differences of the Leukemogenic Properties of p210 BCR/ABL1 and p185 BCR/ABL1

Pia Radszuweit, Fulya Korkmaz, Barbara Mankel, Rahel Fitzel, Estelle Erkner, Hildegard Keppeler, Claudia Lengerke, Dominik Schneidawind, Corina Schneidawind

Blood (2022) 140 (Supplement 1): 5879.

https://doi.org/10.1182/blood-2022-169414

Published: 2022

Journal Articles

Different MLL Breakpoints Influence Leukemia Characteristics of MLL -Rearranged Cells in a Human CRISPR/Cas9-Based Model

Rahel Fitzel, Sarah Brüstl, Fulya Korkmaz, Barbara Mankel, Estelle Erkner, Hildegard Keppeler, Claudia Lengerke, Dominik Schneidawind, Corina Schneidawind

Blood (2022) 140 (Supplement 1): 5857.

https://doi.org/10.1182/blood-2022-169461

Published: 2022

Journal Articles

The Rorɣ/SREBP2 Pathway Is a Master Regulator of Cholesterol Metabolism and Serves As Potential Therapeutic Target in T(4;11) Leukemia

Estelle Erkner, Thomas Hentrich, Rahel Fitzel, Hildegard Keppeler, Fulya Korkmaz, Johan Jeong, Julia Schulze-Hentrich, Claudia Lengerke, Dominik Schneidawind, Corina Schneidawind

Blood (2022) 140 (Supplement 1): 2999–3000.

https://doi.org/10.1182/blood-2022-169267

Published: 2022

Journal Articles

Invariant Natural Killer T Cells from Donor Lymphocyte Infusions (DLI-iNKTs) Contribute to Anti-Tumor Immunity after Allogeneic Hematopoietic Cell Transplantation

Simona Jahnke, Hannes Schmid, MSc, Kathy-Ann Secker, MSc, Silke Duerr-Stoerzer, Hildegard Keppeler, Rebecca Baur, Michael Schumm, Dr. MD vet., Rupert Handgretinger, MD PhD, Wolfgang Bethge, MD, Lothar Kanz, Corina Schneidawind, MD, Dominik Schneidawind, MD

Blood (2018) 132 (Supplement 1): 3340.

https://doi.org/10.1182/blood-2018-99-111745

Published: 2018

Journal Articles

Inhibition of DOT1L and PRMT5 Promotes Anti-Tumor Activity in a Human MLL Leukemia Model Induced By CRISPR/Cas9

Kathy-Ann Secker, MSc, Hildegard Keppeler, Silke Duerr-Stoerzer, Hannes Schmid, MSc, Dominik Schneidawind, MD, Thomas Hentrich, PhD, Julia Schulze-Hentrich, PhD, Barbara Mankel, Falko Fend, MD, Lothar Kanz, Corina Schneidawind, MD

Blood (2018) 132 (Supplement 1): 5147.

https://doi.org/10.1182/blood-2018-99-115975

Published: 2018

Journal Articles

Myc Drives MLL Leukemogenesis in a Human CRISPR/Cas9 Leukemia Model and Indirect Inhibition with JQ1 Diminishes Leukemia Activity

Kathy-Ann Secker, MSc, Hildegard Keppeler, Silke Duerr-Stoerzer, Hannes Schmid, MSc, Dominik Schneidawind, MD, Thomas Hentrich, PhD, Julia Schulze-Hentrich, PhD, Lothar Kanz, Corina Schneidawind, MD

Blood (2018) 132 (Supplement 1): 2213.

https://doi.org/10.1182/blood-2018-99-114419

Published: 2018

Journal Articles

Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells

Jing Du, Katelyn Paz, Govindarajan Thangavelu, Dominik Schneidawind, Jeanette Baker, Ryan Flynn, Omar Duramad, Colby Feser, Angela Panoskaltsis-Mortari, Robert S. Negrin, Bruce R. Blazar

Blood (2017) 129 (23): 3121–3125.

https://doi.org/10.1182/blood-2016-11-752444

Published: 2017

Journal Articles

TNF-α priming enhances CD4 + FoxP3 + regulatory T-cell suppressive function in murine GVHD prevention and treatment

Antonio Pierini, William Strober, Caitlin Moffett, Jeanette Baker, Hidekazu Nishikii, Maite Alvarez, Yuqiong Pan, Dominik Schneidawind, Everett Meyer, Robert S. Negrin

Blood (2016) 128 (6): 866–871.

https://doi.org/10.1182/blood-2016-04-711275

Published: 2016

Includes: Supplemental data

Journal Articles

Increased Activity in the T Cell Effector Phase and Enhanced T Cell Repertoire Target-Tissue Stability Distinguish Alloreactivity Across Major Versus Minor Histocompatibility Barriers

Pingping Zheng, PhD, Adrianne E Vasey, Jeanette Baker, Bettina Iliopoulou, PhD, Dennis B Leveson-Gower, PhD, Antonio Pierini, Dominik Schneidawind, MD, Xiaoqing You, PhD, Katie Hsu, Robert Negrin, MD, Everett Meyer, MD PhD

Blood (2015) 126 (23): 4284.

https://doi.org/10.1182/blood.V126.23.4284.4284

Published: 2015

Journal Articles

Expanded CD4+Foxp3+ Regulatory T Cells through DR3 Signaling Have a Distinct Immunophenotype and Abrogate the Lethal Acute-Graft and Host Disease after Allogeneic Transplantation

Hidekazu Nishikii, MD, PhD, Byung-Su Kim, MD, Yasuhisa Yokoyama, MD,PhD, Jeanette Baker, PhD, Antonio Pierini, MD, Maite Alvarez, PhD, Yuqiong Pan, MD, PhD, Yan Chen, MD, Dominik Schneidawind, MD, Shigeru Chiba, MD, PhD, Robert Negrin, MD

Blood (2015) 126 (23): 1876.

https://doi.org/10.1182/blood.V126.23.1876.1876

Published: 2015

Journal Articles

TNF-Alpha Priming Enhances CD4 + FoxP3 + Regulatory T Cell Suppressive Function in GvHD Prevention and Treatment

Antonio Pierini, MD, Caitlin Moffett, Dominik Schneidawind, MD, Jeanette Baker, PhD, Hidekazu Nishikii, MD PhD, Yuqiong Pan, MD, PhD, Maite Alvarez, PhD, Everett Meyer, MD PhD, Robert Negrin, MD

Blood (2015) 126 (23): 1885.

https://doi.org/10.1182/blood.V126.23.1885.1885

Published: 2015

Journal Articles

MLL leukemia induction by genome editing of human CD34 + hematopoietic cells

Corina Buechele, Erin H. Breese, Dominik Schneidawind, Chiou-Hong Lin, Johan Jeong, Jesus Duque-Afonso, Stephen H. K. Wong, Kevin S. Smith, Robert S. Negrin, Matthew Porteus, Michael L. Cleary

Blood (2015) 126 (14): 1683–1694.

https://doi.org/10.1182/blood-2015-05-646398

Published: 2015

Includes: Supplemental data

Journal Articles

Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease

Byung-Su Kim, Hidekazu Nishikii, Jeanette Baker, Antonio Pierini, Dominik Schneidawind, Yuqiong Pan, Andreas Beilhack, Chung-Gyu Park, Robert S. Negrin

Blood (2015) 126 (4): 546–557.

https://doi.org/10.1182/blood-2015-04-637587

Published: 2015

Includes: Supplemental data

Journal Articles

Third-party CD4 + invariant natural killer T cells protect from murine GVHD lethality

Dominik Schneidawind, Jeanette Baker, Antonio Pierini, Corina Buechele, Richard H. Luong, Everett H. Meyer, Robert S. Negrin

Blood (2015) 125 (22): 3491–3500.

https://doi.org/10.1182/blood-2014-11-612762

Published: 2015

Includes: Supplemental data

Journal Articles

Loss of CD62L Expression in CD4+FoxP3+ Regulatory T Cells Following Freeze-and-Thaw Prevents Protection Against GVHD in Murine Models

Mareike Florek, MD, Dominik Schneidawind, MD, Jeanette Baker, PhD, Antonio Pierini, MD, Dennis B Leveson-Gower, PhD, Yuqiong Pan, MD, Robert S. Negrin, MD, Everett H. Meyer, MD PhD

Blood (2014) 124 (21): 2427.

https://doi.org/10.1182/blood.V124.21.2427.2427

Published: 2014

NARROW

Characterization of a Human Bone Marrow-Derived CRISPR/Cas9 Cell Model for Chronic Myeloid Leukemia

Tisagenlecleucel for the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: An Interim Report of the European Post-Authorisation Safety Study Conducted By EBMT

Prognostic Impact of t(9;11) and Del(7q) As Intermediate-Risk Abnormalities in AML Following Allo-Transplant: Insights from the ELN 2022 Classification - an EBMT ALWP Study

High Body Mass Index Is Associated with Favorable Outcome in Younger Patients Receiving CD19 CAR T-Cell Therapy for B-Cell Lymphoma: A Retrospective Study from the EBMT Transplant Complications Working Party

Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Induction of t(9;22) (q34;q11) in Bone Marrow-Derived HSPCs Via CRISPR/Cas9 to Reveal the Differences of the Leukemogenic Properties of p210 BCR/ABL1 and p185 BCR/ABL1

Different MLL Breakpoints Influence Leukemia Characteristics of MLL -Rearranged Cells in a Human CRISPR/Cas9-Based Model

The Rorɣ/SREBP2 Pathway Is a Master Regulator of Cholesterol Metabolism and Serves As Potential Therapeutic Target in T(4;11) Leukemia

Invariant Natural Killer T Cells from Donor Lymphocyte Infusions (DLI-iNKTs) Contribute to Anti-Tumor Immunity after Allogeneic Hematopoietic Cell Transplantation

Inhibition of DOT1L and PRMT5 Promotes Anti-Tumor Activity in a Human MLL Leukemia Model Induced By CRISPR/Cas9

Myc Drives MLL Leukemogenesis in a Human CRISPR/Cas9 Leukemia Model and Indirect Inhibition with JQ1 Diminishes Leukemia Activity

Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells

TNF-α priming enhances CD4 + FoxP3 + regulatory T-cell suppressive function in murine GVHD prevention and treatment

Increased Activity in the T Cell Effector Phase and Enhanced T Cell Repertoire Target-Tissue Stability Distinguish Alloreactivity Across Major Versus Minor Histocompatibility Barriers

Expanded CD4+Foxp3+ Regulatory T Cells through DR3 Signaling Have a Distinct Immunophenotype and Abrogate the Lethal Acute-Graft and Host Disease after Allogeneic Transplantation

TNF-Alpha Priming Enhances CD4 + FoxP3 + Regulatory T Cell Suppressive Function in GvHD Prevention and Treatment

MLL leukemia induction by genome editing of human CD34 + hematopoietic cells

Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease

Third-party CD4 + invariant natural killer T cells protect from murine GVHD lethality

Loss of CD62L Expression in CD4+FoxP3+ Regulatory T Cells Following Freeze-and-Thaw Prevents Protection Against GVHD in Murine Models

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only